VELO Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Financial Calendar for 2020

Veloxis Pharmaceuticals Announces Financial Calendar for 2020

Company Release no. 23/2019

To: NASDAQ Copenhagen A/S                                                             

Copenhagen, Denmark, 30 December 2019

 

Veloxis Pharmaceuticals Announces Financial Calendar for 2020

 

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2020. 

The full calendar is shown below.

18 March 2020:     Deadline for Veloxis’s Receipt of Shareholder Proposals for the 2020 Annual General Meeting.
31 March 2020: 2019 Annual Report.
29 April 2020: 2020 Annual General Meeting. 
13 May 2020:   Q1 Interim Report – for the period 1 January to 31 March, 2020.
12 August 2020:     Q2 Interim Report – for the period 1 January to 30 June, 2020.
10 November 2020:   Q3 Interim Report – for the period 1 January to 30 September, 2020.

 

For more information, please contact:

 Craig Alexander Collard    Ira Duarte
 President & CEO  CFO
 Phone: 0  Phone:
 Email:   Email:

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

For further information, please visit

 

Attachment

EN
30/12/2019

Underlying

VELOVeloxis Pharmaceuticals A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Veloxis Pharmaceuticals A/S

 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 Febru...

Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Company Release no. 13/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 17 February 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Today, Veloxis Pharmaceuticals A/S' Extraordinary General Meeting passed the following resolutions: The following persons were elected as members of the Board of Directors: Masaya EtohDaisuke MatsuoMatthew Ryan Dumont                    The elected board members replace all current membe...

February 17, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmace...

Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 12/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, 29. januar 2020   Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S   Som meddelt ved selskabsmeddelelse nr. 10/2020 har Veloxis Pharmaceuticals A/S ("Veloxis"), eft...

January 29, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Reques...

Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S Company Release no. 12/2020 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 29 January 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S As announced in company release no. 10/2020, Veloxis Pharmaceuticals A/S ("Veloxis") has, upon request from Asahi Kasei Pharma Denmark A/S, requested Nasdaq Copenhagen A/S ("Nasdaq Cop...

January 29, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Notice to Convene Extraordinary General Meeting

Notice to Convene Extraordinary General Meeting Company Announcement no. 11/2020 To: NASDAQ Copenhagen A/S                                           Copenhagen, Denmark, 24 January 2020 Notice to Convene Extraordinary General Meeting Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (the "Company"), hereby convenes an extraordinary general meeting in the Company to be held on Monday 17 February 2020 at 12:00 p.m. CET at the offices o...

January 24, 2020 1 EN
 PRESS RELEASE
Free
VELO Veloxis Pharmac...

Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceutical...

Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 10/2020 Til: NASDAQ Copenhagen A/S                                                  København, Danmark, fredag den 24. januar 2020 Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Med henvisning til selskabsmeddelelse nr. 9/2020, i hvilken Asahi Kasei Pharma Denmark A/S offentliggjorde sin beslutning om at udnytte sin ret til at gennemføre en tvangsindløsning af aktierne ejet af Vel...

January 24, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch